Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne-Marie C Dingemans

Showing results (1-10 of 220) with videos related to

Pageof 22
Sort By:
Expert Opinion on Investigational Drugs|March 10, 2017
Heat shock protein antagonists in early stage clinical trials for NSCLCLizza E L Hendriks, Anne-Marie C Dingemans
Expert Opinion on Investigational Drugs|October 8, 2011
Low molecular weight heparins in the treatment of lung cancerWouter W Mellema, Egbert F Smit, Anne-Marie C Dingemans
Nederlands Tijdschrift Voor Geneeskunde|March 23, 2011
[EGFR-mutation in non-small cell lung carcinoma. Treatment with tyrosine kinase inhibitors possible]Erik Thunnissen, Egbert F Smit, Petra M Nederlof, et al.
Cancers|July 2, 2021
Reporting of Incidence and Outcome of Bone Metastases in Clinical Trials Enrolling Patients with Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma-A Systematic ReviewAnita Brouns, Safiye Dursun, Gerben Bootsma, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 11, 2012
Response assessment using 18F-FDG PET early in the course of radiotherapy correlates with survival in advanced-stage non-small cell lung cancerWouter van Elmpt, Michel Ollers, Anne-Marie C Dingemans, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2018
Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoringMart Schiefer, Lizza E L Hendriks, Trang Dinh, et al.
Expert Opinion on Investigational Drugs|July 25, 2014
Phase II drugs that are currently in development for the treatment of cachexiaAnne-Marie C Dingemans, Judith de Vos-Geelen, Ramon Langen, et al.
Plos One|July 7, 2011
MicroRNA expression and clinical outcome of small cell lung cancerJih-Hsiang Lee, Johannes Voortman, Anne-Marie C Dingemans, et al.
International Journal of Chronic Obstructive Pulmonary Disease|May 2, 2019
Cross-sectional and longitudinal assessment of muscle from regular chest computed tomography scans: L1 and pectoralis muscle compared to L3 as reference in non-small cell lung cancerKarin J C Sanders, Juliette H R J Degens, Anne-Marie C Dingemans, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 18, 2018
New Insights into the Molecular Characteristics of Pulmonary Carcinoids and Large Cell Neuroendocrine Carcinomas, and the Impact on Their Clinical ManagementJules L Derks, Noémie Leblay, Sylvie Lantuejoul, et al.
Pageof 22

Showing results (1-10 of 220) with videos related to

Sort By:
Pageof 22
Expert Opinion on Investigational Drugs|March 10, 2017
Heat shock protein antagonists in early stage clinical trials for NSCLCLizza E L Hendriks, Anne-Marie C Dingemans
Expert Opinion on Investigational Drugs|October 8, 2011
Low molecular weight heparins in the treatment of lung cancerWouter W Mellema, Egbert F Smit, Anne-Marie C Dingemans
Nederlands Tijdschrift Voor Geneeskunde|March 23, 2011
[EGFR-mutation in non-small cell lung carcinoma. Treatment with tyrosine kinase inhibitors possible]Erik Thunnissen, Egbert F Smit, Petra M Nederlof, et al.
Cancers|July 2, 2021
Reporting of Incidence and Outcome of Bone Metastases in Clinical Trials Enrolling Patients with Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma-A Systematic ReviewAnita Brouns, Safiye Dursun, Gerben Bootsma, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 11, 2012
Response assessment using 18F-FDG PET early in the course of radiotherapy correlates with survival in advanced-stage non-small cell lung cancerWouter van Elmpt, Michel Ollers, Anne-Marie C Dingemans, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2018
Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoringMart Schiefer, Lizza E L Hendriks, Trang Dinh, et al.
Expert Opinion on Investigational Drugs|July 25, 2014
Phase II drugs that are currently in development for the treatment of cachexiaAnne-Marie C Dingemans, Judith de Vos-Geelen, Ramon Langen, et al.
Plos One|July 7, 2011
MicroRNA expression and clinical outcome of small cell lung cancerJih-Hsiang Lee, Johannes Voortman, Anne-Marie C Dingemans, et al.
International Journal of Chronic Obstructive Pulmonary Disease|May 2, 2019
Cross-sectional and longitudinal assessment of muscle from regular chest computed tomography scans: L1 and pectoralis muscle compared to L3 as reference in non-small cell lung cancerKarin J C Sanders, Juliette H R J Degens, Anne-Marie C Dingemans, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 18, 2018
New Insights into the Molecular Characteristics of Pulmonary Carcinoids and Large Cell Neuroendocrine Carcinomas, and the Impact on Their Clinical ManagementJules L Derks, Noémie Leblay, Sylvie Lantuejoul, et al.
Pageof 22